Related Experiment Video
Updated: Apr 6, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.3K
Disease-modifying strategies for Parkinson's disease
Lorraine V Kalia1,2,3,4, Suneil K Kalia4,5, Anthony E Lang1,2,3,4
1Division of Neurology, Department of Medicine, Toronto Western Hospital, University of Toronto, Canada.
Summary
Despite numerous failures in clinical trials for Parkinson's disease (PD) modifying therapies, research continues. New targets and ongoing studies offer hope for slowing neurodegeneration in Parkinson's disease.
Area of Science:
- Neurodegenerative disease research
- Clinical trial analysis
- Parkinson's disease therapeutics
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder with significant patient and healthcare burdens.
- Effective disease-modifying therapies for PD are lacking, despite extensive research.
- Recent clinical trials for agents like coenzyme Q10 and creatine have yielded negative results.
Purpose of the Study:
- To review clinical trials for disease-modifying therapies in Parkinson's disease published since 2013.
- To summarize ongoing clinical trials for PD.
- To discuss current challenges and promising future approaches in PD therapy development.
Main Methods:
- Systematic review of published clinical trial data for PD therapies (2013-present).
- Compilation and analysis of ongoing PD clinical trials.
- Discussion of molecular pathways and preclinical models relevant to PD.
Main Results:
- Multiple disease-modifying therapies investigated in recent trials have failed to show efficacy.
- Despite setbacks, understanding of PD molecular pathways has advanced, identifying new therapeutic targets.
- At least eight clinical trials are currently underway, testing novel agents and strategies like AAV2-GDNF and α-synuclein immunization.
Conclusions:
- The development of effective disease-modifying therapies for Parkinson's disease remains a significant challenge.
- Continued research into molecular pathways and novel therapeutic strategies is crucial.
- Ongoing clinical trials represent the next wave of potential treatments for slowing PD progression.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:28Drug Therapy
411
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
411
01:37Neural Regulation
44.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.9K
01:21EPS and iPS Cells in Disease Research
3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K